Pre-treatment with silymarin reduces brain myeloperoxidase activity and inflammatory cytokines in 6-OHDA hemi-parkinsonian rats

Neuroscience Letters

Volumn 555, Issue , 2013, Pages 106-111

  Haddadi, Rasool ^a,b   Mohajjel Nayebi, Alireza ^a,b   Brooshghalan, Shahla Eyvari ^a  

^a TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TABRIZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 OHDA; Catalepsy; IL 6; Myeloperoxidase; Silymarin; TNF

Indexed keywords

BRAIN ENZYME; CYTOKINE; INTERLEUKIN 6; MYELOPEROXIDASE; NEUROTOXIN; SILYMARIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN REGION; CATALEPSY; CEREBROSPINAL FLUID; CONTROLLED STUDY; ENZYME ACTIVITY; MALE; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; RAT;

6-OHDA; CATALEPSY; IL-6; MYELOPEROXIDASE; SILYMARIN; TNF-Α;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CATALEPSY; CORPUS STRIATUM; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; INTERLEUKIN-6; MALE; NEUROPROTECTIVE AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; PEROXIDASE; RATS; RATS, WISTAR; SILYMARIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84885215165     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.09.022     Document Type: Article

References (38)

1. Baluchnejadmojarad T., Roghani M., Mafakheri M. Neuroprotective effect of silymarin in 6-hydroxydopamine hemi-parkinsonian rat: involvement of estrogen receptors and oxidative stress. Neuroscience Letters 2010, 480:206-210.
2. Barone F.C., Hillegass L., Price W., White R., Lee E., Feuerstein G., Sarau H., Clark R., Griswold D. Polymorphonuclear leukocyte infiltration into cerebral focal ischemic tissue: myeloperoxidase activity assay and histologic verification. Journal of Neuroscience Research 1991, 29:336-345.
3. Block M., Hong J. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochemical Society Transactions 2007, 35:1127-1132.
4. Bosisio E., Benelli C., Pirola O. Effect of the flavanolignans of Silybum marianum L. On lipid peroxidation in rat liver microsomes and freshly isolated hepatocytes. Pharmacological Research 1992, 25:147-165.
5. Brodacki B., Staszewski J., Toczyłowska B., Kozłowska E., Drela N., Chalimoniuk M., Stepien A. Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism. Neuroscience Letters 2008, 441:158-162.
6. Choi D.K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.C., Jackson-Lewis V., Vila M., Vonsattel J.P., Heinecke J.W. Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. Journal of Neuroscience 2005, 25:6594-6600.
7. Cicchetti F., Brownell A., Williams K., Chen Y., Livni E., Isacson O. Neuroinflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. European Journal of Neuroscience 2002, 15:991-998.
8. Colton C., Gilbert D. Microglia an in vivo source of reactive oxygen species in the brain. Advances in Neurology 1993, 59:321.
9. Green P.S., Mendez A.J., Jacob J.S., Crowley J.R., Growdon W., Hyman B.T., Heinecke J.W. Neuronal expression of myeloperoxidase is increased in Alzheimer's disease. Journal of Neurochemistry 2004, 90:724-733.
10. Gupta O., Sing S., Bani S., Sharma N., Malhotra S., Gupta B., Banerjee S., Handa S. Anti-inflammatory and anti-arthritic activities of silymarin acting through inhibition of 5-lipoxygenase. Phytomedicine 2000, 7:21-24.
11. Hirsch E.C., Hunot S. Neuroinflammation in Parkinson's disease: a target for neuroprotection?. Lancet Neurology 2009, 8:382-397.
12. Hou Y.-C., Liou K.-T., Chern C.-M., Wang Y.-H., Liao J.-F., Chang S., Chou Y.-H., Shen Y.-C. Preventive effect of silymarin in cerebral ischemia-reperfusion-induced brain injury in rats possibly through impairing NF-κB and STAT-1 activation. Phytomedicine 2010, 17:963-973.
13. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. Journal of Neuroscience 2000, 20:6309-6316.
14. Klebanoff S.J., Clark R.A. The Neutrophil Function and Clinical Disorders 1978.
15. Kraft A.D., Harry G.J. Features of microglia and neuroinflammation relevant to environmental exposure and neurotoxicity. International Journal of Environmental Research and Public Health 2011, 8:2980-3018.
16. Manna S.K., Mukhopadhyay A., Van N.T., Aggarwal B.B. Silymarin suppresses TNF-induced activation of NF-κB, c-Jun N-terminal kinase, and apoptosis. Journal of Immunology 1999, 163:6800-6809.
17. McGeer P., Itagaki S., Boyes B., McGeer E. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988, 38:1285-1285.
18. Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients. Neuroscience Letters 1994, 180:147-150.
19. Mogi M., Harada M., Riederer P., Narabayashi H., Fujita K., Nagatsu T. Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neuroscience Letters 1994, 165:208-210.
20. Mogi M., Togari A., Tanaka K., Ogawa N., Ichinose H., Nagatsu T. Increase in level of tumor necrosis factor (TNF)-α in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic l-DOPA on the TNF-α induction. Neuroscience Letters 1999, 268:101-104.
21. Muzes G., Deak G., Lang I., Nekam K., Gergely P., Feher J. Effect of the bioflavonoid silymarin on the in vitro activity and expression of superoxide dismutase (SOD) enzyme. Acta Physiologica Hungarica 1991, 78:3-9.
22. Nagatsu T., Mogi M., Ichinose H., Togari A. Changes in cytokines and neurotrophins in Parkinson's disease. Journal of Neural Transmission-Supplements only 2000, 277-290.
23. Nagra R.M., Becher B., Tourtellotte W.W., Antel J.P., Gold D., Paladino T., Smith R.A., Nelson J.R., Reynolds W.F. Immunohistochemical and genetic evidence of myeloperoxidase involvement in multiple sclerosis. Journal of Neuroimmunology 1997, 78:97-107.
24. Nayebi M., Reyhani-Rad S., Saberian M., Azimzadeh S., Samini M. Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rat. Pharmacological Reports 2010, 62:258-264.
25. Nencini C., Giorgi G., Micheli L. Protective effect of silymarin on oxidative stress in rat brain. Phytomedicine 2007, 14:129-135.
26. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates 2007, Academic Press, London.
27. Qin L., Wu X., Block M.L., Liu Y., Breese G.R., Hong J.S., Knapp D.J., Crews F.T. Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration. Glia 2007, 55:453-462.
28. Raza S.S., Khan M.M., Ashafaq M., Ahmad A., Khuwaja G., Khan A., Siddiqui M.S., Safhi M.M., Islam F. Silymarin protects neurons from oxidative stress associated damages in focal cerebral ischemia: a behavioral, biochemical and immunohistological study in Wistar rats. Journal of the Neurological Sciences 2011, 309:45-54.
29. Reynolds W.F., Rhees J., Maciejewski D., Paladino T., Sieburg H., Maki R.A., Masliah E. Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease. Experimental Neurology 1999, 155:31-41.
30. Roghani M., Behzadi G. Neuroprotective effect of vitamin E on the early model of Parkinson's disease in rat: behavioral and histochemical evidence. Brain Research 2001, 892:211-217.
31. Samii A., Etminan M., Wiens M.O., Jafari S. NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies. Drugs & Aging 2009, 26:769-779.
32. Sawada M., Imamura K., Nagatsu T. Role of cytokines in inflammatory process in Parkinson's disease. Parkinson's Disease and Related Disorders 2006, 373-381.
33. Schwarting R., Huston J. The unilateral 6-hydroxydopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Progress in Neurobiology 1996, 50:275-331.
34. Shadrina M., Slominsky P., Limborska S. 6 Molecular mechanisms of pathogenesis of Parkinson's disease. Journal of Pediatric, Maternal & Family Health-Chiropractic 2010, 281:229.
35. Singhal N.K., Srivastava G., Patel D.K., Jain S.K., Singh M.P. Melatonin or silymarin reduces maneb-and paraquat-induced Parkinson's disease phenotype in the mouse. Journal of Pineal Research 2011, 50:97-109.
36. Tsai M.-J., Liao J.-F., Lin D.-Y., Huang M.-C., Liou D.-Y., Yang H.-C., Lee H.-J., Chen Y.-T., Chi C.-W., Huang W.-C. Silymarin protects spinal cord and cortical cells against oxidative stress and lipopolysaccharide stimulation. Neurochemistry International 2010, 57:867-875.
37. Wang M.J., Lin W.W., Chen H.L., Chang Y.H., Ou H.C., Kuo J.S., Hong J.S., Jeng K.C.G. Silymarin protects dopaminergic neurons against lipopolysaccharide-induced neurotoxicity by inhibiting microglia activation. European Journal of Neuroscience 2002, 16:2103-2112.
38. Warner T.T., Schapira A.H.V. Genetic and environmental factors in the cause of Parkinson's disease. Annals of Neurology 2003, 53:S16-S25.